優良臨床試驗中心

組長   張義芳 醫師

研究人員

李秉澤 博士
朱洧樂、陳嘉文、謝慶璋、張軒邦

進駐研究醫師：林建鴻、陳功深、蘇穎文、蘇迺文 張育誠、江翊豪、宋孟達

支援醫檢師： 細胞與再生醫療中心 周宛蓉

優良臨床試驗中心主要著重在癌症治療與血液疾病等方面研究。

癌症研究： 

臨床試驗。臨床試驗中，需檢測許多相關項目，以評估臨床試驗之安全性、特異性或成效，為試驗結果提供實證。本實驗室對於院內臨床試驗，進行相關研究項目之檢測。

個人醫學研究，有多項研究結果指出在癌症病人治療用藥時，化療藥物之藥理機轉與基因多型性關係密切，大大影響藥物治療成效，故在病人化療之前，分析相關藥理基因，可提供病人個人用藥參考。

利用次世代定序(NGS)分析病人檢體，探討癌症基因、致病機轉、用藥等多方面研究。

免疫細胞分析：分析病人在接受化療、標靶藥物治療之後，免疫細胞的分子表現及功能差異。

發展CART細胞治療。

血液疾病： 

探討臨床血液疾病及用藥。例如在ET/PV病人觀察其BAFF分子表現及機制探討。

建立斑馬魚模式，分析臨床檢體研究基因與血液疾病的關聯性，來進一步探討血液疾病致病機轉及治療。

本實驗室成立於99年4月，已執行多項院內、院外研究計畫及臨床試驗，並發表多篇論文，期能更進一步了解血液疾病及癌症用藥之作用機轉、效益與安全性，在追求治療效果的同時，也保障病人的用藥安全與生活品質。

Chang PS, Chen YC, Hua WK, Hsu JC, Tsai JC, Huang YW, Kao YH, Wu PH, Wang PN, Chang YF, Chang MC, Chang YC, Jian SL, Lai JS, Lai MT, Yang WC, Shen CN, Wen KK, Wu SC. Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system. PLoS One 2024; 19(8):e0309245. (SCIE, MULTIDISCIPLINARY SCIENCES) (IF: 2.9, Ranking: 32/134=23.88%)

Wang C, Su NW, Hsu K, Kao CW, Chang MC, Chang YF, Lim KH, Chiang YH, Chang YC, Sung MT, Wu HH, Chen CG. The implication of serum HLA-G in angiogenesis of multiple myeloma. Molecular Medicine 2024; 30(1):86. (SCIE, BIOCHEMISTRY & MOLECULAR BIOLOGY) (IF: 6.0, Ranking: 50/313=15.97%)

Chang YC, Tsai HJ, Huang TY, Su NW, Su YW, Chang YF, Chen CG, Lin J, Chang MC, Chen SJ, Chen HC, Lim KH, Chang KC, Kuo SH. Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations. Annals of Hematology 2024;103(8):2917-2930. (SCIE, HEMATOLOGY) (IF: 3.0, Ranking: 32/97=32.98%)

Lu HJ, Hsieh MC, Wang HM, Hsieh JC, Yen CJ, Wu SY, Huang HC, Wang HC, Chu PY, Chen TH, Chien CY, Huang TL, Chang YF, Hua CH, Lien MY, Chen JP, Lu WC, Lin JC, Wang CC, Liu YC, Yang MH, Lou PJ. Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database. Head & Neck 2024; 46(5):1063-1073. (SCIE, OTORHINOLARYNGOLOGY) (IF: 2.7, Ranking: 6/66=9.09%)

Su NW, Dai SH, Hsu K, Chang KM, Ko CC, Kao CW, Chang YF, Chen CG. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma. Cancer Immunology and Immunotherapy CII 2024; 73(1):3. (SCIE, ONCOLOGY) (IF: 4.6, Ranking: 76/322=23.60%)

Wu CE, Liao YH, Wu CL, Yen RF, Lin CC, Yang MH, Yen CC, Su WC, Yen CJ, Chang YF, Wu MF, Yang Y, Lin CY, Yang WC, Wang HC, Li CY, Ho YY, Chang YY, Wu CS, Hsu HC, Chen KH, Huang Y, Chen CJ, Chuang PJ, Lai YC, Huang YY, Tseng NC, Huang YT, Chu CY, Wen-Cheng Chang J. Clinical practice consensus for the diagnosis and management of melanoma in Taiwan. Journal of the Formosan Medical Association 2024; 123(1):7-15. (SCIE, MEDICINE, GENERAL & INTERNAL) (IF: 2.6, Ranking: 71/329=21.58%)

Hsu C, Chang YF, Yen CJ, Xu YW, Dong M, Tong YZ. Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study. BMC Medicine 2023; 21(1):395. (SCIE, MEDICINE, GENERAL & INTERNAL) (IF: 7.0, Ranking: 24/329=7.29%)

Su CW, Lee JC, Chang YF, Su NW, Lee PH, Dai KY, Tai HC, Leu YS, Chen YJ. Delta-volume radiomics of induction chemotherapy to predict outcome of subsequent chemoradiotherapy for locally advanced hypopharyngeal cancer. Tumori 2022; 108(5):450-460. (SCIE, ONCOLOGY) (IF: 2.4, Ranking: 194/322=60.24%)

Lin HC, Saputra F, Audira G, Lai YH, Roldan MJM, Alos HC, Aventurado CA, Vasquez RD, Tsai GJ, Lim KH, Hsiao CD. Investigating potential cardiovascular toxicity of two anti-leukemia drugs of asciminib and ponatinib in zebrafish embryos. International Journal of Molecular Sciences 2022; 23(19):11711. (SCIE, BIOCHEMISTRY & MOLECULAR BIOLOGY) (IF: 4.9, Ranking: 66/313=21.08%)

Chou SC, Chang YC, Liao CK, Chen TC, Sun KJ, Huang WH, Wu YF. New presentations and exacerbations of immune thrombocytopenia after coronavirus disease 2019 vaccinations: the Taiwan experience. Platelets 2022; 148:340-347. (SCIE, HEMATOLOGY) (IF: 2.5, Ranking: 41/97=42.26%)

Su YW, Huang WY, Lin HC, Liao PN, Lin CY, Lin XY, Huang SH, Chen YT, Wu PS. Silmitasertib, a casein kinase 2 inhibitor, induces massive lipid droplet accumulation and non-apoptotic cell death in head and neck cancer cells. Journal of Oral Pathology & Medicine 2022; 1-10. (SCIE, PATHOLOGY, Dentistry, Oral Surgery & Medicine) (IF: 2.7, Ranking: 35/158=22.15%)

Chang YC, Chiang YH, Hsu K, Chuang CK, Kao CW, Chang YF, Chang MC, Lim KH, Cheng HI, Hsu YN, Chen CG. Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Blood Cancer Journal 2021; 11(11):182. (SCIE, MEDICINE, Hematology) (IF: 12.9, Ranking: 5/97=5.15 %)

Wang CI, Chang YF, Sie ZL, Ho AS, Chang JS, Peng CL, Cheng CC. Irradiation suppresses IFNγ-mediated PD-L1 and MCL1 expression in EGFR-positive lung cancer to augment CD8+ T cells cytotoxicity. Cells 2021; 10(10):2515. (SCIE, CELL BIOLOGY) (IF: 5.1, Ranking: 63/205=30.73 %)

Cheng CC, Chang YF, Ho AS, Sie ZL, Chang CL, Chang CC. Irradiation mediates IFNα and CXCL9 expression in non-small cell lung cancer to stimulate CD8+ T cells activity and migration toward tumors. Biomedicines 2021; 9(10):1349. (SCIE, PHARMACOLOGY & PHARMACY) (IF: 3.9, Ranking: 85/354=24.01 %)

Su CW, Lee JC, Chang YF, Su NW, Lee PH, Dai KY, Tai HC, Leu YS, Chen YJ. Delta-volume radiomics of induction chemotherapy to predict outcome of subsequent chemoradiotherapy for locaaly advanced hypopharyngeal cancer. Tumori 2021; 108(5):450-460. (SCIE, ONCOLOGY) (IF: 2.4, Ranking: 194/322=60.24 %)

Lim KH, Wu JN, Huang TY, Jhuang JY, Chang YC, Lin HC, Chiang YH, Su YW, Chen GS, Chang YF, Lim J. Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing. Blood Advances 2021; 5(6):1733-36. (SCIE, HEMATOLOGY) (IF: 7.4, Ranking: 12/97=12.37 %)

Cheng CC, Lin HC, Chiang YW, Chang J, Sie ZL, Yang BL, Lim KH, Peng CL, Ho AS, Chang YF. Nicotine exhausts CD8+ T cells against tumor cells through increasing miR-629-5p to repress IL2RB-mediated granzyme B expression. Cancer Immunology and Immunotherapy CII 2021; 70(5):1351-1364. (SCIE, ONCOLOGY) (IF: 4.6, Ranking: 76/322=23.60%)

Yang CL, Chao YJ, Wang HC, Hou YC, Chen CG, Chang CC, Shan YS. Local ablation of gastric cancer by reconstituted apolipoprotein B lipoparticles carrying epigenetic drugs. Nanomedicine: Nanotechnology, Biology, and Medicine 2021; 37:102450(1-12). (SCIE, MEDICINE, RESEARCH & EXPERIMENTAL) (IF: 4.2, Ranking: 60/189=31.74%)

Lim KH, Chen LC, Hsu K, Chang CC, Chang CY, Kao CW, Chang YF, Chang MC, Chen CG. BAFF-driven NLRP3 inflammasome activation in B cells. Cell Death & Disease 2020; 11(9):820. (SCIE, CELL BIOLOGY) (IF: 6.1, Ranking: 49/205=23.90%)